Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

2015 Faqs


What is known about idarucizumab for dabigatran reversal?

What is the optimal duration of dual antiplatelet therapy after percutaneous coronary intervention?

What is the role of topical tranexamic acid to prevent postsurgical bleeding from major cardiovascular and orthopedic procedures?


What are the key features of the most recent guidelines for the management of patients with atrial fibrillation?

What recent evidence describes the comparative safety and efficacy of bivalirudin and heparins in patients undergoing percutaneous coronary intervention?

Can the intravenous formulation of vitamin K be administered orally?


Can angiotensin receptor blockers (ARBs) be administered to patients who develop angioedema on angiotensin-converting enzyme inhibitor (ACEI) therapy?

What are the data to support the use of ethanol lock therapy to decrease catheter-related infections in pediatric patients?

What is the cross-reactivity of penicillins and carbapenems in a patient with a penicillin allergy?


Can intermittent proton pump inhibitor dosing be used in acute upper gastrointestinal bleeding?

What data support the safety and efficacy of the intravenous P2Y12 inhibitor cangrelor?

Is the recently updated cholesterol guideline cost-effective and better at identifying at-risk patients than the previous ATP III guideline?


How will fusion technology for factor concentrates change prophylaxis strategies in the management of hemophilia A and B?

How should allergic reactions to local anesthetics be managed?

What is the efficacy and safety evidence for Zarxio (filgrastim-sndz), the first biosimilar approved in the United States?


What are the new recommendations for 13-valent pneumococcal conjugate vaccine (PCV13) in older adults?

What is the safety information available on the use of NOACs in patients with renal impairment?

How should patients receiving new oral anticoagulants be managed prior to planned surgical procedures?


What is the evidence to support twice-daily dosing of insulin glargine?

What is the rationale and significance of the FDA’s new guidance for abuse-deterrent opioids?

What should healthcare providers know about PCSK9 inhibitors, the new class of cholesterol-lowering medications?


What evidence supports the efficacy of the new antibiotic, ceftazidime/avibactam (Avycaz)?

What should healthcare providers know about the recent measles outbreak in the United States?

What are the current recommendations for managing patients initiating non-VKA oral anticoagulants (NOACs) after receiving thrombolytic therapies for pulmonary embolism?


What drugs should be avoided in myasthenia gravis?

Is normal saline or heparin preferred as a catheter flush solution?

Should warfarin be resumed after gastrointestinal bleeding, and if so – when?


What are the new guidelines for the pharmacological management of obesity?

What information is available on the use of peramivir for treatment of influenza?

What data supports the use of new oral anticoagulants in special populations (hepatic impairment, obesity, pregnancy, lactation, and pediatrics)?


What are the new recommendations for direct-acting antivirals for treatment of hepatitis C virus?

What is the Evidence for Use of Inhaled Epoprostenol?

What vaccines should be administered to adult, splenectomized, patients?


What is the Evidence for Use of Bronchodilators in Bronchiolitis?

What are Current Recommendations for Treatment of Drug Extravasation?

Is Vancomycin Therapy with Targeted Troughs Between 15 and 20 mg/L Associated with an Increased Risk of Nephrotoxicity?